<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03759522</url>
  </required_header>
  <id_info>
    <org_study_id>R18-118</org_study_id>
    <nct_id>NCT03759522</nct_id>
  </id_info>
  <brief_title>Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.</brief_title>
  <acronym>DPA-714</acronym>
  <official_title>Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to measure the concentration and the regional brain
      distribution of activated brain microglia/macrophages using the PET radiopharmaceutical
      [F-18]DPA-714 in individuals with chronic pain and fatigue suspected to be associated with
      neuroinflammation. The PET tracer [F-18]DPA-714 binds to the 18 kDa translocator protein
      (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated
      microglia/macrophages and provides a non-invasive measure of neuroinflammation. The primary
      objective of this study is to determine if pain and fatigue patients have higher levels of
      neuroinflammation than HC individuals as measured with [F-18]DPA-714-PET/MRI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neuroinflammation will be measured in healthy volunteers and compared to neuroinflammation in individuals with pain and fatigue, as measured with [F-18]DPA-714-PET/MRI.</measure>
    <time_frame>3 years</time_frame>
    <description>Quantitative PET measures of TSPO binding in brain regions including cerebral cortex, thalami, and brainstem will be compared between healthy volunteers and symptomatic study participants with pain and/or fatigue.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Fibromyalgia</condition>
  <condition>Chronic Fatigue Syndrome</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibromyalgia Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Fatigue Syndrome Subjets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Sclerosis Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DPA-714 PET/MRI</intervention_name>
    <description>DPA-714 PET/MRI</description>
    <arm_group_label>Chronic Fatigue Syndrome Subjets</arm_group_label>
    <arm_group_label>Fibromyalgia Subjects</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Multiple Sclerosis Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 to 65 years of age

          2. Healthy volunteer OR Clinical diagnosis of Multiple Sclerosis (MS) OR Meets 2016
             American College of Rheumatology (ACR) case definition criteria for fibromyalgia OR
             Meets 1994 Fukuda case definition criteria for Chronic Fatigue Syndrome

        Exclusion Criteria:

          1. Contraindication to MRI

          2. Pregnancy

          3. Lactation

          4. Individuals who are unable to participate in the imaging portion due to severity of
             their medical condition

          5. Chronic infectious disease (e.g. HIV, HCV)

          6. Viral or bacterial illness requiring medical attention and/or antibiotics within 1
             month of study participation

          7. Diagnosis of cancer, including leukemia

          8. Blood or blood clotting disorder

          9. Except for individuals with MS, a diagnosis of autoimmune disease is exclusionary

         10. Positive urine Î²-hCG test day of procedure or a serum -hCG test within 48 hours prior
             to the administration of [18F]DPA-714

         11. Currently enrolled in a clinical trial utilizing experimental therapies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan McConathy, MD, PhD</last_name>
    <phone>205-996-7115</phone>
    <email>jmcconathy@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>April Riddle, BSRT</last_name>
    <phone>205-934-6504</phone>
    <email>ariddle@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan McConathy, MD</last_name>
      <phone>205-996-7115</phone>
      <email>jmcconathy@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan McConathy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bag Asim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bhambhvani Pradeep, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Choudhary Gagandeep, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geldmacher David, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lapi Suzanne, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffers Charlotte Denise, RPh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natelson Marissa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberson Erik, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2018</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jonathan E McConathy</investigator_full_name>
    <investigator_title>M.D. P.h.D., Director for the Division Molecular Imaging and Therapeutics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

